78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp acquired a new position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 78,653 shares of the biopharmaceutical company's stock, valued at approximately $240,000. Mackenzie Financial Corp owned approximately 0.16% of Puma Biotechnology at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in PBYI. Tower Research Capital LLC TRC increased its stake in Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 6,351 shares in the last quarter. Graham Capital Management L.P. acquired a new position in shares of Puma Biotechnology during the fourth quarter valued at about $33,000. ProShare Advisors LLC bought a new stake in shares of Puma Biotechnology during the fourth quarter worth about $36,000. C2C Wealth Management LLC acquired a new stake in shares of Puma Biotechnology in the 4th quarter worth about $37,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Puma Biotechnology in the 4th quarter worth about $54,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Stock Down 3.2%

PBYI traded down $0.12 during mid-day trading on Monday, reaching $3.60. 386,689 shares of the stock were exchanged, compared to its average volume of 445,893. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock has a market capitalization of $178.67 million, a PE ratio of 7.50 and a beta of 1.29. The company has a 50 day moving average price of $3.11 and a two-hundred day moving average price of $3.10.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PBYI. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.